<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00727532</url>
  </required_header>
  <id_info>
    <org_study_id>NU 07U1</org_study_id>
    <secondary_id>P30CA060553</secondary_id>
    <secondary_id>NU-IRB-STU00003123</secondary_id>
    <nct_id>NCT00727532</nct_id>
  </id_info>
  <brief_title>Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer</brief_title>
  <official_title>Correlation of Pathologic Findings After Neo-adjuvant Sorafenib With Results of Diffusion-Weighted Magnetic Resonance Imaging in Patients With Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib before
      surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be
      removed.

      PURPOSE: This clinical trial is studying how well sorafenib works in treating patients with
      locally advanced or metastatic kidney cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To demonstrate the feasibility and safety of sorafenib tosylate when given prior to
           nephrectomy or metastasectomy.

        -  To evaluate the ability of diffusion-weighted magnetic resonance imaging (DW-MRI) to
           detect early and ongoing microstructural changes in primary and metastatic renal cell
           carcinoma lesions during neoadjuvant therapy with sorafenib tosylate.

        -  To correlate early and ongoing microstructural changes in primary and metastatic renal
           cell carcinoma lesions with pathologic and clinical findings at the time of nephrectomy
           or metastasectomy.

        -  To evaluate the ability of changes in DW-MRI to predict subsequent favorable response to
           treatment (complete or partial response or stable disease) after 4 weeks of therapy.

      OUTLINE: Patients receive oral sorafenib tosylate twice daily on days 1-28. Patients then
      undergo a nephrectomy or metastasectomy in week 5. Patients with residual metastatic disease
      may continue sorafenib tosylate twice daily and undergo a diffusion-weighted MRI (DW-MRI)
      every 8 weeks in the absence of disease progression or unacceptable toxicity.

      Patients undergo a DW-MRI of the abdomen and pelvis at baseline and prior to week 5 to
      evaluate microstructure tumor changes and to allow for prediction of sorafenib tosylate
      benefit. DW-MRI results are correlated with surgical and pathologic findings obtained at week
      5.

      Resected tumor tissue are analyzed for vascular density and to distinguish apoptotic cell
      death from necrotic cell death via immunohistochemistry and to measure apoptotic cell death
      via TUNEL assay.

      After completion of study treatment, patients are followed every 3 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low Accrual
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Difference in Apparent Diffusion Coefficient Between Baseline and Week 5</measure>
    <time_frame>Baseline and week 5</time_frame>
    <description>Mean Difference in Apparent Diffusion Coefficient [Time Frame: Baseline and Week 5] To assess whether changes in the apparent diffusion coefficient (ADC) during neoadjuvant sorafenib treatment are detectable in locally advanced or metastatic kidney cancer. The ADC value will be calculated at baseline (within 28 days of initiating sorafenib) and Week 5, and the mean difference will be calculated. The percent change between this mean difference is reported. Week 5 ADC value minus baseline ADC value/divided by baseline ADC value was calculated for each participant. Apparent diffusion coefficient (ADC), obtained by measuring diffusion values at magnetic resonance imaging (MRI), is a measure of water mobility. Lower values correspond to tumor and higher values are consistent with cysts. With sorafenib therapy, the amount of free water may increase in a lesion due to necrosis, and as a result the ADC may increase in value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Tumor Size From Baseline to Approximately 29-34 Days After Completion of Neoadjuvant Sorafenib Treatment</measure>
    <time_frame>Just prior to study week 5</time_frame>
    <description>Tumors were measured at baseline and approximately 29-34 days after completion of neoadjuvant treatment with sorafenib (just prior to surgery). Tumors were assessed by RECIST response criteria.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hereditary Clear Cell Renal Cell Carcinoma</condition>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients undergo pre-treatment DW-MRI of the abdomen and pelvis. Patient then receive Sorafenib 400mg orally twice daily on days 1-28. Following completion of 28 days of sorafenib, patients obtain a second DW-MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>400mg by mouth twice daily for 28 consecutive days</description>
    <arm_group_label>Sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed newly diagnosed clear cell renal cell carcinoma, meeting 1 of
             the following criteria:

               -  Localized disease, as evidenced by intact, bulky, and primary renal lesions (T1 &gt;
                  3 cm, any T2, T3, or T4) appropriate for nephrectomy

               -  Limited metastatic disease, as evidenced by any renal primary (T1 &gt; 3 cm, any T2,
                  T3, or T4) appropriate for cytoreductive nephrectomy

               -  Isolated abdominal/pelvic recurrence with limited metastatic burden (minimum size
                  &gt; 2 cm) appropriate for metastasectomy

          -  No known brain metastasis

               -  Patients with neurological symptoms must undergo a CT scan/MRI of the brain to
                  exclude brain metastasis

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group performance status 0-1

          -  Hemoglobin ≥ 9.0 g/dL

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  Alanine aminotransferase and Aspartate aminotransferase ≤ 2.5 times ULN (≤ 5 times ULN
             with liver involvement)

          -  Creatinine ≤ 1.5 times ULN

          -  Estimated glomerular filtration rate &gt; 30 mL/min (for patients receiving Gd-enhanced
             MRI)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception prior to, during (men and women),
             and for at least 3 months after (men) completion of study therapy

          -  Adequate cardiac and pulmonary status for operative therapy

          -  No active clinically serious infection &gt; CTCAE grade 2

          -  No known HIV, hepatitis B, or hepatitis C infections

          -  No serious non-healing wound, ulcer, or bone fracture

          -  No significant traumatic injury within the past 4 weeks

          -  No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 within the past 4 weeks

          -  No other hemorrhage/bleeding event ≥ CTCAE grade 3 within the past 4 weeks

          -  No history of an uncontrolled bleeding disorder including, but not limited to, any of
             the following:

               -  Bleeding diathesis

               -  Coagulopathy

          -  No cardiac disease or condition including, but not limited to, any of the following:

               -  New York Heart Association class II-IV congestive heart failure

               -  Unstable angina (anginal symptoms at rest)

               -  New onset angina beginning within the last 3 months

               -  Myocardial infarction within the past 6 months

               -  Cardiac ventricular arrhythmias requiring antiarrhythmic therapy

          -  No uncontrolled hypertension (i.e., systolic blood pressure [BP] &gt; 150 mm Hg or
             diastolic BP &gt; 100 mm Hg) despite optimal medical management

          -  No thrombolic or embolic events within the past 6 months (e.g., cerebrovascular
             accident including transient ischemic attacks)

          -  No condition that impairs the ability to swallow whole pills

          -  No malabsorption problem

          -  No contraindication to MRI, including, but not limited to, any of the following:

               -  Ferromagnetic implants

               -  Dental work

               -  Pacemakers

               -  Metallic implants

               -  Severe claustrophobia which precludes closed MRI testing

          -  No known or suspected allergy to sorafenib tosylate

          -  No contraindication or allergy to gadolinium (e.g., end stage renal disease requiring
             hemodialysis)

          -  No intercurrent illness or situation which, in the judgment of the investigator, would
             affect assessments of clinical status and study endpoints significantly

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 4 weeks since prior major surgery or open biopsy

          -  No prior therapy with tyrosine kinase or vascular endothelial growth factor inhibitors
             (e.g., sunitinib malate, sorafenib, or bevacizumab)

          -  No concurrent Hypericum perforatum (St. John's wort) or rifampin

          -  No concurrent use of illicit drugs or other substances that may, in the opinion of the
             investigator, have a reasonable chance of contributing to toxicity or interfering with
             study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy M. Kuzel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 1, 2008</study_first_submitted>
  <study_first_submitted_qc>August 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2008</study_first_posted>
  <results_first_submitted>April 7, 2016</results_first_submitted>
  <results_first_submitted_qc>April 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 3, 2019</results_first_posted>
  <last_update_submitted>April 30, 2019</last_update_submitted>
  <last_update_submitted_qc>April 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clear cell renal cell carcinoma</keyword>
  <keyword>hereditary clear cell renal cell carcinoma</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage I renal cell cancer</keyword>
  <keyword>stage II renal cell cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was open to enrollment at Northwestern University beginning June 2008, and closed to enrollment in September 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib</title>
          <description>Sorafenib 400mg orally twice daily on days 1-28
sorafenib tosylate: 400mg by mouth twice daily for 28 consecutive days
diffusion-weighted magnetic resonance imaging: At baseline and just prior to surgery after sorafenib treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib</title>
          <description>Sorafenib 400mg orally twice daily on days 1-28</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Renal cell carcinoma Clinical Staging</title>
          <description>Participants must have bulky (T1&gt;3cm,any T2, T3,orT4) renal cell carcinoma undergoing nephrectomy.Staging defined as:T1&gt;3cm: Tumor ≤7cm in greatest dimension but &gt;3cm, limited to the kidney;T2:Tumor &gt;7cm, limited to the kidney;T3:Tumor extends into major veins but not into the ipsilateral adrenal gland &amp; not beyond Gerota fascia (the fibrous layer that surrounds the kidney &amp; nearby fatty tissue);T4:Tumor invades beyond Gerota fascia(including contiguous extension into ipsilateral adrenal gland).The higher the number after the T, the larger the tumor or more it has grown into nearby tissues.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>T1&gt;3cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Difference in Apparent Diffusion Coefficient Between Baseline and Week 5</title>
        <description>Mean Difference in Apparent Diffusion Coefficient [Time Frame: Baseline and Week 5] To assess whether changes in the apparent diffusion coefficient (ADC) during neoadjuvant sorafenib treatment are detectable in locally advanced or metastatic kidney cancer. The ADC value will be calculated at baseline (within 28 days of initiating sorafenib) and Week 5, and the mean difference will be calculated. The percent change between this mean difference is reported. Week 5 ADC value minus baseline ADC value/divided by baseline ADC value was calculated for each participant. Apparent diffusion coefficient (ADC), obtained by measuring diffusion values at magnetic resonance imaging (MRI), is a measure of water mobility. Lower values correspond to tumor and higher values are consistent with cysts. With sorafenib therapy, the amount of free water may increase in a lesion due to necrosis, and as a result the ADC may increase in value.</description>
        <time_frame>Baseline and week 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib</title>
            <description>Sorafenib 400mg orally twice daily on days 1-28
sorafenib tosylate: 400mg by mouth twice daily for 28 consecutive days
diffusion-weighted magnetic resonance imaging: At baseline and just prior to surgery after sorafenib treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Difference in Apparent Diffusion Coefficient Between Baseline and Week 5</title>
          <description>Mean Difference in Apparent Diffusion Coefficient [Time Frame: Baseline and Week 5] To assess whether changes in the apparent diffusion coefficient (ADC) during neoadjuvant sorafenib treatment are detectable in locally advanced or metastatic kidney cancer. The ADC value will be calculated at baseline (within 28 days of initiating sorafenib) and Week 5, and the mean difference will be calculated. The percent change between this mean difference is reported. Week 5 ADC value minus baseline ADC value/divided by baseline ADC value was calculated for each participant. Apparent diffusion coefficient (ADC), obtained by measuring diffusion values at magnetic resonance imaging (MRI), is a measure of water mobility. Lower values correspond to tumor and higher values are consistent with cysts. With sorafenib therapy, the amount of free water may increase in a lesion due to necrosis, and as a result the ADC may increase in value.</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.57" lower_limit="-59.00" upper_limit="49.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Tumor Size From Baseline to Approximately 29-34 Days After Completion of Neoadjuvant Sorafenib Treatment</title>
        <description>Tumors were measured at baseline and approximately 29-34 days after completion of neoadjuvant treatment with sorafenib (just prior to surgery). Tumors were assessed by RECIST response criteria.</description>
        <time_frame>Just prior to study week 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib</title>
            <description>Sorafenib 400mg orally twice daily on days 1-28
sorafenib tosylate: 400mg by mouth twice daily for 28 consecutive days
diffusion-weighted magnetic resonance imaging: At baseline and just prior to surgery after sorafenib treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tumor Size From Baseline to Approximately 29-34 Days After Completion of Neoadjuvant Sorafenib Treatment</title>
          <description>Tumors were measured at baseline and approximately 29-34 days after completion of neoadjuvant treatment with sorafenib (just prior to surgery). Tumors were assessed by RECIST response criteria.</description>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.34" lower_limit="-15.3" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percentage Change of Necrosis From Baseline to Surgery</title>
        <description>Changes in MRI will be correlated with findings of necrosis. Amount of necrosis will be measured at baseline and at time of surgery. Percentage change for necrosis will be calculated from baseline and time of surgery.</description>
        <time_frame>At time of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib</title>
            <description>Sorafenib 400mg orally twice daily on days 1-28
sorafenib tosylate: 400mg by mouth twice daily for 28 consecutive days
diffusion-weighted magnetic resonance imaging: At baseline and just prior to surgery after sorafenib treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change of Necrosis From Baseline to Surgery</title>
          <description>Changes in MRI will be correlated with findings of necrosis. Amount of necrosis will be measured at baseline and at time of surgery. Percentage change for necrosis will be calculated from baseline and time of surgery.</description>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.13" lower_limit="-38.32" upper_limit="92.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events assessed for 28 days prior to surgical resection</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib</title>
          <description>Sorafenib 400mg orally twice daily on days 1-28
sorafenib tosylate: 400mg by mouth twice daily for 28 consecutive days
diffusion-weighted magnetic resonance imaging: At baseline and just prior to surgery after sorafenib treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-Foot Skin Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis/Stomatitis (functional symptomatic) - Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Transaminitis</sub_title>
                <description>alanine aminotransferase, aspartate aminotransferase, or both</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hand-Foot Skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial did not reach the original goal of 10 subjects. Only 9 out of 10 patients had been enrolled, with no accrual for a period of more than 1 year. Therefore it was administratively closed by the Data Monitoring Committee.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Results Entry Administrator</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-1301</phone>
      <email>croqualityassurance@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

